Sponsor: BioAlta, LLC
Sponsor Study ID: BA3021-001
Study Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination With Nivolumab In Patients With Advanced Solid Tumors
CTO #: 103465
NCT Number: NCT03504488
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors